SAR.L
Sareum Holdings plc
1W: +0.1%
1M: +3.5%
3M: +12.9%
YTD: -8.7%
1Y: -11.3%
3Y: -85.9%
5Y: -84.9%
£17.00 ($0.23)
+1.00 (+6.25%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap£22.1M ($0.3M)
52W Range9.5-29
Volume114,902
Avg Volume209,156
Beta-1.06
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOStephen Barry Parker DPhil
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2004-10-11
Websitesareum.com
Langford Arch
Cambridge CB22 3FX
GB
Cambridge CB22 3FX
GB
44 1223 497 700
About Sareum Holdings plc
Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.
Recent Insider Trades
No insider trades found